Com.Pl.it DX® Liquid

The Com.Pl.it DX® Liquid test can be conducted before to selecting a treatment and for tumor surveillance throughout therapy. It also aids in identifying secondary mutations, which may necessitate adjustments to the treatment regimen.

Selecting a Suitable Treatment Strategy for Each Solid Tumor:

Com.Pl.it DX® Liquid is intended for all solid tumors and offers real-time insights into the tumor’s genetic profile through the non-invasive technique of liquid biopsy.

The Com.Pl.it DX® Liquid multigene liquid biopsy test is primarily indicated for:

• Patients with inoperable neoplasms and those with insufficient or inadequate tissue samples.
• Individuals having numerous metastases.
• Patients receiving treatment or post-treatment.

Patients receiving treatment or post-treatment.

-The Com.Pl.it DX® Liquid biopsy test aids in formulating a treatment strategy.
-It ascertains the molecular profile (gene mutations) of the tumor and the relationships among genes in instances of numerous mutations.
-Identifies on-label medications, if relevant, that target either the mutant genes or the associated pathways.
-Identifies variants linked to resistance against targeted medicines.

Identifies off-label therapies or interventions in clinical trials informed by tumor genetic profiling. This may be especially significant for those for whom conventional treatment has been ineffective.